

# News Release



## Regulatory News Service

---

2 January 2026

### Transparency Directive *Voting rights and capital*

The following notification is made in accordance with the UK Financial Conduct Authority's Disclosure and Transparency Rule 5.6.1. As at 31 December 2025 the issued share capital of AstraZeneca PLC with voting rights is 1,550,907,927 ordinary shares of US\$0.25. No shares are held in Treasury. Therefore, the total number of voting rights in AstraZeneca PLC is 1,550,907,927.

The above figure for the total number of voting rights may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, AstraZeneca PLC under the UK Financial Conduct Authority's Disclosure and Transparency Rules.

#### AstraZeneca

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca's innovative medicines are sold in more than 125 countries and used by millions of patients worldwide. Please visit [astrazeneca.com](http://astrazeneca.com) and follow the Company on social media [@AstraZeneca](https://twitter.com/AstraZeneca)

#### Contacts

For details on how to contact the Investor Relations Team, please click [here](#). For Media contacts, click [here](#).

**Matthew Bowden**  
**Company Secretary**  
**AstraZeneca PLC**